Viewing Study NCT00207168


Ignite Creation Date: 2025-12-24 @ 5:31 PM
Ignite Modification Date: 2026-03-06 @ 2:31 PM
Study NCT ID: NCT00207168
Status: COMPLETED
Last Update Posted: 2011-04-22
First Post: 2005-09-12
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine
Sponsor: Bristol-Myers Squibb
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module